Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study Meeting Abstract
| Authors: | Slovin, S. F.; Hamid, O.; Tejwani, S.; Higano, C. S.; Harzstark, A.; Alumkal, J. J.; Scher, H. I.; Chin, K. M.; Gagnier, P.; McHenry, M. B.; Beer, T. M. |
| Abstract Title: | Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study |
| Meeting Title: | 2012 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 30 |
| Issue: | 5 Suppl. |
| Meeting Dates: | 2012 Feb 2-4 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2012-02-10 |
| Language: | English |
| ACCESSION: | WOS:000208892400027 |
| DOI: | 10.1200/jco.2012.30.5_suppl.25 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 25 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
